Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 12/19/2025 | CALL | $230.00 | 7,796 | +7,796 | |
| 12/19/2025 | PUT | $200.00 | 3,082 | +3,082 | |
| 12/19/2025 | CALL | $220.00 | 3,610 | +2,838 | +367.62% |
| 11/21/2025 | PUT | $210.00 | 797 | +422 | +112.53% |
| 12/19/2025 | PUT | $210.00 | 468 | +370 | +377.55% |
| 01/15/2027 | CALL | $220.00 | 210 | +209 | +20,900.00% |
| 11/21/2025 | CALL | $65.00 | 1,268 | -8 | -0.63% |
| 11/21/2025 | PUT | $90.00 | 506 | -10 | -1.94% |
| 11/21/2025 | CALL | $105.00 | 1,238 | -11 | -0.88% |
| 11/21/2025 | CALL | $100.00 | 1,157 | -23 | -1.95% |
| 11/21/2025 | CALL | $115.00 | 129 | -47 | -26.70% |
| 11/21/2025 | PUT | $160.00 | 1,389 | -69 | -4.73% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.51% | 1.8M | 1.98M |
| Vanguard Extended Market Index Fund | 0.77% | 553.14k | 608.45k |
| Fidelity Extended Market Index Fund | 0.49% | 349.73k | 384.7k |
| Fidelity Total Market Index Fund | 0.17% | 123.53k | 135.88k |
| Fidelity Series Total Market Index Fund | 0.11% | 75.48k | 83.02k |
| Fidelity NASDAQ Composite Index Fund | 0.09% | 66.47k | 73.11k |
| Vanguard Balanced Index Fund | 0.07% | 52.83k | 58.11k |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.07% | 48.78k | 53.66k |
| iShares Core S&P Total U.S. Stock Market ETF | 0.01% | 9.59k | 10.54k |
| USAA Mutual Fd Tr-Extended Market Index Fd | 0.01% | 7.48k | 8.22k |
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)
11/14 06:30 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage
10/10 10:55 am
Benzinga
Read moreWhy Cidara Therapeutics Stock Crushed It Today
10/09 06:32 pm
The Motley Fool
Read moreCidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
07/01 04:59 pm
GlobeNewswire Inc.
Read moreCidara Announces Pricing of Upsized Public Offering of Common Stock
06/24 08:00 pm
Benzinga
Read moreCidara Announces Pricing of Upsized Public Offering of Common Stock
06/24 08:00 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
04/01 04:56 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference
11/19 09:00 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
10/04 04:30 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference
09/25 08:00 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
09/19 08:00 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Announces Appointment of Jim Beitel as Chief Business Officer
08/19 05:12 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
07/03 01:06 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
05/30 08:00 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
05/15 04:20 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules
05/15 04:01 pm
GlobeNewswire Inc.
Read moreCytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
05/08 05:10 pm
Zacks Investment Research
Read moreCidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
04/26 08:00 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Announces Divestiture of Rezafungin to Mundipharma* to Focus on Advancing the Clinical Development of Cloudbreak DFC Pipeline
04/24 04:01 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
04/22 05:10 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
04/22 05:06 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Announces Reverse Stock Split
04/22 08:49 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
04/05 03:00 pm
GlobeNewswire Inc.
Read moreTELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates
03/21 05:30 pm
Zacks Investment Research
Read moreEmergent Biosolutions (EBS) Reports Q4 Loss, Tops Revenue Estimates
03/06 06:55 pm
Zacks Investment Research
Read moreCodexis (CDXS) Tops Q4 Earnings and Revenue Estimates
02/28 07:50 pm
Zacks Investment Research
Read moreCidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
01/29 05:30 pm
GlobeNewswire Inc.
Read moreCidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
12/26 11:51 am
Zacks Investment Research
Read moreCidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
12/22 08:30 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
12/06 09:00 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
11/03 12:00 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
11/02 04:15 pm
GlobeNewswire Inc.
Read moreGSK (GSK) Q3 Earnings and Revenues Surpass Estimates
11/01 07:15 am
Zacks Investment Research
Read moreCidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
10/13 10:34 am
GlobeNewswire Inc.
Read moreNurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Misses Revenue Estimates
10/12 05:15 pm
Zacks Investment Research
Read moreCidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
10/11 08:30 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
09/29 04:51 pm
GlobeNewswire Inc.
Read moreCidara to Present at the 25th Annual H.C. Wainwright Global Investment Conference
09/06 04:05 pm
GlobeNewswire Inc.
Read moreWhy Core & Main Are Trading Lower By 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
09/06 01:16 pm
Benzinga
Read moreCidara Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
08/09 08:53 am
Benzinga
Read moreCidara Therapeutics (CDTX) Reports Q2 Loss, Lags Revenue Estimates
08/03 05:25 pm
Zacks Investment Research
Read moreCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
08/03 04:08 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Provides Update on REZZAYO™ (rezafungin for injection)
07/31 04:30 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Provides Update on Status of Ongoing CD388 Influenza Program
07/20 05:00 pm
GlobeNewswire Inc.
Read moreCidara Therapeutics Added to Russell Microcap® Index
06/26 08:00 am
GlobeNewswire Inc.
Read moreCidara Therapeutics Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B
06/22 08:00 am
GlobeNewswire Inc.
Read moreCidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak® Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit
06/20 09:55 am
GlobeNewswire Inc.
Read moreCidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit
06/13 08:00 am
GlobeNewswire Inc.
Read more